treace medical concepts inc - TMCI

TMCI

Close Chg Chg %
4.53 -0.18 -3.97%

Closed Market

4.35

-0.18 (3.97%)

Volume: 218.38K

Last Updated:

Sep 10, 2026, 4:00 PM EDT

Company Overview: treace medical concepts inc - TMCI

TMCI Key Data

Open

$4.46

Day Range

4.31 - 4.52

52 Week Range

1.17 - 7.50

Market Cap

$301.11M

Shares Outstanding

65.03M

Public Float

47.60M

Beta

1.41

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.93

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

326.08K

 

TMCI Performance

1 Week
 
-9.56%
 
1 Month
 
-9.00%
 
3 Months
 
7.14%
 
1 Year
 
-39.75%
 
5 Years
 
-84.08%
 

TMCI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About treace medical concepts inc - TMCI

Treace Medical Concepts, Inc. engages in the designing, manufacturing, and marketing of orthopedic medical devices and biologic solutions. The firm offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.

TMCI At a Glance

Treace Medical Concepts, Inc.
100 Palmetto Park Place
Ponte Vedra Beach, Florida 32081
Phone 1-904-373-5940 Revenue 212.69M
Industry Medical Specialties Net Income -59,002,000.00
Sector Health Technology 2025 Sales Growth 1.592%
Fiscal Year-end 12 / 2026 Employees 450
View SEC Filings

TMCI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.729
Price to Book Ratio 1.792
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.101
Enterprise Value to Sales 0.839
Total Debt to Enterprise Value 0.403

TMCI Efficiency

Revenue/Employee 472,644.444
Income Per Employee -131,115.556
Receivables Turnover 5.01
Total Asset Turnover 1.043

TMCI Liquidity

Current Ratio 4.311
Quick Ratio 3.134
Cash Ratio 1.579

TMCI Profitability

Gross Margin 79.812
Operating Margin -25.461
Pretax Margin -27.741
Net Margin -27.741
Return on Assets -28.946
Return on Equity -58.936
Return on Total Capital -37.063
Return on Invested Capital -34.806

TMCI Capital Structure

Total Debt to Total Equity 82.286
Total Debt to Total Capital 45.141
Total Debt to Total Assets 37.707
Long-Term Debt to Equity 79.656
Long-Term Debt to Total Capital 43.698
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Treace Medical Concepts Inc - TMCI

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
141.84M 187.12M 209.36M 212.69M
Sales Growth
+50.22% +31.92% +11.89% +1.59%
Cost of Goods Sold (COGS) incl D&A
27.52M 35.18M 41.09M 42.94M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.66M 5.35M 8.42M 10.62M
Depreciation
4.66M 4.85M 7.42M 9.62M
Amortization of Intangibles
- 500.00K 1.00M 1.00M
COGS Growth
+54.40% +27.82% +16.80% +4.49%
Gross Income
114.31M 151.94M 168.26M 169.75M
Gross Income Growth
+49.25% +32.91% +10.75% +0.88%
Gross Profit Margin
+80.60% +81.20% +80.37% +79.81%
2022 2023 2024 2025 5-year trend
SG&A Expense
149.16M 203.37M 223.95M 223.91M
Research & Development
13.58M 15.44M 20.59M 20.28M
Other SG&A
135.57M 187.93M 203.36M 203.62M
SGA Growth
+60.21% +36.34% +10.12% -0.02%
Other Operating Expense
- - - -
-
Unusual Expense
4.31M 163.00K 53.00K 2.74M
EBIT after Unusual Expense
(39.15M) (51.59M) (55.74M) (56.89M)
Non Operating Income/Expense
737.00K 7.23M 5.25M 3.21M
Non-Operating Interest Income
- 6.73M 4.88M 2.78M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.40M 5.17M 5.26M 5.32M
Interest Expense Growth
+8.33% +17.49% +1.72% +1.22%
Gross Interest Expense
4.40M 5.17M 5.26M 5.32M
Interest Capitalized
- - - -
-
Pretax Income
(42.81M) (49.53M) (55.74M) (59.00M)
Pretax Income Growth
-108.33% -15.68% -12.55% -5.85%
Pretax Margin
-30.19% -26.47% -26.63% -27.74%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(42.81M) (49.53M) (55.74M) (59.00M)
Minority Interest Expense
- - - -
-
Net Income
(42.81M) (49.53M) (55.74M) (59.00M)
Net Income Growth
-108.33% -15.68% -12.55% -5.85%
Net Margin Growth
-30.19% -26.47% -26.63% -27.74%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(42.81M) (49.53M) (55.74M) (59.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(42.81M) (49.53M) (55.74M) (59.00M)
EPS (Basic)
-0.7746 -0.8139 -0.8975 -0.9326
EPS (Basic) Growth
-102.30% -5.07% -10.27% -3.91%
Basic Shares Outstanding
55.28M 60.85M 62.11M 63.27M
EPS (Diluted)
-0.7746 -0.8139 -0.8975 -0.9326
EPS (Diluted) Growth
-102.30% -5.07% -10.27% -3.91%
Diluted Shares Outstanding
55.28M 60.85M 62.11M 63.27M
EBITDA
(30.19M) (46.08M) (47.27M) (43.53M)
EBITDA Growth
-90.77% -52.63% -2.59% +7.91%
EBITDA Margin
-21.28% -24.62% -22.58% -20.47%

Snapshot

Average Recommendation HOLD Average Target Price 4.667
Number of Ratings 5 Current Quarters Estimate -0.254
FY Report Date 09 / 2026 Current Year's Estimate -0.85
Last Quarter’s Earnings -0.24 Median PE on CY Estimate N/A
Year Ago Earnings -0.93 Next Fiscal Year Estimate -0.775
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate -0.25 -0.07 -0.85 -0.77
High Estimates -0.24 -0.05 -0.83 -0.63
Low Estimate -0.27 -0.11 -0.88 -0.89
Coefficient of Variance -4.32 -30.72 -2.79 -13.15

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Treace Medical Concepts Inc - TMCI

Date Name Shares Transaction Value
Apr 21, 2026 Mark L. Hair Chief Financial Officer 952,002 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00

Treace Medical Concepts Inc in the News